REG - Destiny Pharma PLC - Director/PDMR Shareholding

Destiny PharmaAnnouncement

27/02/2023 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230227:nRSa1965Ra&default-theme=true

RNS Number : 1965R  Destiny Pharma PLC  27 February 2023

 

 

 

Destiny Pharma plc

 

("Destiny Pharma" or the "Company")

 

Director Dealing

 

 

Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology
company focused on the development of novel medicines that can prevent
life-threatening infections, announces that it was notified on 27 February
2023 that on that same day, Nick Rodgers, Chairman of the Company, purchased
20,000 ordinary shares of 1 pence in the Company ("Ordinary Shares") at a
price of 33.94 pence.

Following the purchase, Mr. Rodgers' beneficial interest in the Company is
126,073 Ordinary Shares, representing 0.17 per cent. of the total issued share
capital.

 

For further information, please contact:

 

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0)20 7220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

Optimum Strategic Communications

Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper

+44 (0) 203 922 0891

DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

Stern IR - US

Janhavi Mohite

+1-212-362-1200

Janhavi.Mohite@sternir.com

 

 

About Destiny Pharma

 

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has completed a positive Phase 2b clinical trial targeting the prevention of
post-surgical staphylococcal hospital infections including MRSA. It is also
co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of
COVID-19 and other viral respiratory infections and has earlier grant funded
XF drug research projects.

 

For further information on the Company, please
visit  https://www.destinypharma.com (https://www.destinypharma.com/)
 

 

 

 

 

Further information is disclosed below pursuant to Article 19(3) of the Market
Abuse Regulation.

 

 1.                        Details of the person discharging managerial responsibilities / person closely
                           associated
 a)                        Name                                                         Nick Rodgers
 2.                        Reason for the Notification
 a)                        Position/status                                              Chairman
 b)                        Initial notification/Amendment                               Initial Notification
 3.                        Details of the issuer, emission allowance market participant, auction
                           platform, auctioneer or auction monitor
 a)                        Name                                                         Destiny Pharma plc
 b)                        LEI                                                          213800O9WH9Z38EHAC95
 4.                        Details of the transaction(s): section to be repeated for (i) each type of
                           instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                           place where transactions have been conducted
 a)                        Description of the Financial instrument, type of instrument  Ordinary shares of 1 pence each in Destiny Pharma Plc
                           Identification code                                          GB00BDHSP575
 b)                        Nature of the transaction                                    Purchase of Ordinary Shares
 c)                        Price(s) and volume(s)                                       Price(s)     Volume(s)
                                                                                        33.94 pence  20,000
 d)                        Aggregated information:

                           ·      Aggregated volume                                     See 4c) above

                           ·      Price
 e)                        Date of the transaction                                      27 February 2023
 f)                        Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

d)

Aggregated information:

·      Aggregated volume

·      Price

 

See 4c) above

e)

Date of the transaction

27 February 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFVRFIIDFIV